Assignee
LUMOSA THERAPEUTICS CO LTD
TW·6 granted patents·10 pending applications·4 citations·filing 2016–2024
Top patents by PatentIndex Score
16 records- 0190US11707501B2Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugateLUMOSA THERAPEUTICS CO LTD·Filed 2022·Granted Jul 25, 2023·2 cites·14 claims
- 0287US11338008B2Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugateLUMOSA THERAPEUTICS CO LTD·Filed 2020·Granted May 24, 2022·2 cites·6 claims
- 0379US12059448B2Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugateLUMOSA THERAPEUTICS CO LTD·Filed 2023·Granted Aug 13, 2024·0 cites·15 claims
- 0479US2025186534A1Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugateLUMOSA THERAPEUTICS CO LTD·Filed 2024·Application pending·0 cites
- 0565US11241424B2Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2019·Granted Feb 8, 2022·0 cites·37 claims
- 0661US2022056149A1Single-domain antibody-cytosine deaminase fusion proteinsLUMOSA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 0760US11234974B2Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2018·Granted Feb 1, 2022·0 cites·16 claims
- 0860US2024016794A1Method for treating acute ischemic strokeLUMOSA THERAPEUTICS CO LTD·Filed 2023·Application pending·0 cites
- 0959US2022071987A1Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 1057US2022362226A1Compositions and methods for treating pruritusLUMOSA THERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 1152US2019202931A1Single-domain antibody-cytosine deaminase fusion proteinsLUMOSA THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 1251US2019298702A1Compositions and methods for treating pruritusLUMOSA THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 1350US2021330667A1Topical composition of nalbuphine and method for treating pruritus condition, pain, or inflammatory condition by using the sameLUMOSA THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 1449US10183018B2Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2016·Granted Jan 22, 2019·0 cites·6 claims
- 1548US2020179373A1Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2020·Application pending·0 cites
- 1643US2020030318A1Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine esterLUMOSA THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LUMOSA THERAPEUTICS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →